Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 24,341 | 13,987 | 7,735 | 15,146 | 5,750 |
| Cost of Goods | 1,384 | 6,381 | 742 | 478 | 684 |
| Gross Profit | 22,957 | 7,606 | 6,993 | 14,668 | 5,066 |
| Operating Expenses | 269,364 | 692,416 | 162,122 | 555,980 | 264,820 |
| Operating Income | -246,023 | -684,429 | -154,387 | -540,834 | -259,070 |
| Other Income | -60,024 | 459,190 | 53,402 | -22,349 | -16,751 |
| Pre-tax Income | -306,047 | -225,239 | -100,985 | -563,183 | -275,821 |
| Income Tax | 38 | 401 | 93 | -22 | -224 |
| Net Income Continuous | -306,085 | -225,640 | -101,078 | -563,161 | -275,597 |
| Minority Interests | -21,549 | -17,159 | -18,895 | -53,597 | -14,568 |
| Net Income | $-284,536 | $-208,481 | $-82,183 | $-509,564 | $-261,029 |
| EPS Basic Total Ops | -0.41 | -0.32 | -0.13 | -0.79 | -0.41 |
| EPS Basic Continuous Ops | -0.45 | -0.35 | -0.16 | -0.87 | -0.44 |
| EPS Diluted Total Ops | -0.41 | -0.32 | -0.13 | -0.79 | -0.41 |
| EPS Diluted Continuous Ops | -0.45 | -0.35 | -0.16 | -0.87 | -0.44 |
| EBITDA(a) | $-244,653 | $-684,429 | $-154,387 | $-540,834 | $-259,070 |